Contents:

1 Executive Summary 2 About Cancer Highlights 3 Methodologies 4 Table of Contents 4.1 List of Figures 4.2 List of Tables 5 Introduction 5.1 The Scope of this Report 5.2 Definitions 5.3 Abbreviations 6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 6.1 Drug Repositioning in Oncology 6.2 Introduction to Lung Cancer Drug Targets 6.2.1 Carboxy-lyase Activity Targets 6.2.2 Catalytic ActivityTargets 6.2.3 Cell Adhesion Molecule Activity Targets 6.2.4 Chaperone ActivityTargets 6.2.5 Chemokine Activity Targets 6.2.6 Complement Activity Targets 6.2.7 Cysteine-Type Peptidase Activity Targets 6.2.8 Cytokine Activity Targets 6.2.9 DNA Binding Targets 6.2.10 DNA Repair Protein Targets 6.2.11 DNA Topoisomerase Activity Targets 6.2.12 DNA-Directed DNA Polymerase Activity Targets 6.2.13 DNA-methyltransferase Activity Targets 6.2.14 Extracellular Ligand-Gated Ion Channel Activity Targets 6.2.15 Extracellular Matrix Structural Constituent Targets 6.2.16 G-protein Coupled Receptor Activity Targets 6.2.17 Glutathione Transferase Activity Targets 6.2.18 Growth Factor Activity Targets 6.2.19 GTPase Activity Targets 6.2.20 Hormone activity Targets 6.2.21 Hydrolase Activity Targets 6.2.22 Ion channel Activity Targets 6.2.23 Kinase Activity Targets 6.2.24 Kinase regulator activity Targets 6.2.25 Ligase Activity Targets 6.2.26 Lipase Activity Targets 6.2.27 Lipid Kinase Activity Targets 6.2.28 Metallopeptidase Activity Targets 6.2.29 Molecular Function Unknown Targets 6.2.30 Motor Activity Targets 6.2.31 Oxidoreductase Activity Targets 6.2.32 Peptidase Activity Targets 6.2.33 Peroxidase Activity Targets 6.2.34 Phosphoric Diester Hydrolase Activity Targets 6.2.35 Protein binding Targets 6.2.36 Protein Serine/Threonine Kinase Activity Targets 6.2.37 Protein Threonine/Tyrosine Kinase Activity Targets 6.2.38 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 6.2.39 Protein-Tyrosine Kinase Activity Targets 6.2.40 Receptor Activity Targets 6.2.41 Receptor binding Targets 6.2.42 Receptor Signaling Complex Scaffold Activity Targets 6.2.43 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 6.2.44 RNA Binding Targets 6.2.45 RNA-Directed DNA Polymerase Activity Targets 6.2.46 Serine-Type Peptidase Activity Targets 6.2.47 Structural Constituent of Cytoskeleton Targets 6.2.48 Transcription Factor Activity Targets 6.2.49 Transcription Regulator Activity Targets 6.2.50 Transcription Regulator Activity Targets 6.2.51 Transferase Activity Targets 6.2.52 Transmembrane Receptor Activity Targets 6.2.53 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 6.2.54 Transporter Activity Targets 6.2.55 Ubiquitin-Specific Protease Activity Targets 6.2.56 Other Targets 6.3 The Cancer Genome Project and Lung Cancer Targets 6.3.1 Lung Cancer Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 6.4 Structure-based Drug Design in Lung Cancer is Stimulated by Available Structure Data on Biological Targets 6.5 Target-Target Interactions among Identified Lung Cancer Targets 6.6 The Drug-Target Interactome 6.7 Protein Expression Levels of Identified Drug Targets of Lung Cancer Drugs 6.8 Pathway Analysis of Lung Cancer Drug Targets 7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lung Cancer Pipeline? 7.1 Terminated Drug Target Profiles in Lung Cancer 7.2 Pre-Registration to being Marketed: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 7.3 Phase III Clinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 7.4 Phase II Clinical Development: New and Unique Drug Target Profiles the Lung Cancer Pipeline 7.5 Phase I Clinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 7.6 Preclinical Development: New and Unique Drug Target Profiles in the Lung Cancer Pipeline 7.7 Development Profiles of All Lung Cancer Drug Target Profiles 8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Pipeline by Type of Compound 8.1 Small Molecules 8.1.1 Background 8.1.2 Targets in Lung Cancer 8.2 Peptide/Protein Drugs 8.2.1 Background 8.2.2 Targets in Lung Cancer 8.3 Antibodies and Antibody-like Structures 8.3.1 Background 8.3.2 Targets in Lung Cancer 8.4 Nucleic Acid Therapies 8.4.1 Background 8.4.2 Targets in Lung Cancer 8.5 Gene Therapy 8.5.1 Background 8.5.2 Targets in Lung Cancer 8.6 Drug Delivery and Nanotechnology 8.6.1 Background 8.6.2 Targets in Lung Cancer 8.7 The Competition Through Close Mechanistic Approximation Among Drugs in Lung Cancer 8.8 Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets 9 Selecting a Sub-Indication of Lung Cancer for Drug Development 9.1 Lung Cancer (general) 9.1.1 Players and their Compared Pipeline 9.1.2 Where is the Real Competition? 9.1.3 How Successful are They in Their Targeting Strategy? 9.2 Non-Small Cell Lung Cancer 9.2.1 Players and their Compared Pipeline 9.2.2 Where is the Real Competition? 9.2.3 How Successful are They in Their Targeting Strategy? 9.3 Small Cell Lung Cancer 9.3.1 Players and their Compared Pipeline 9.3.2 Where is the Real Competition? 9.3.3 How Successful are They in Their Targeting Strategy? 10 Portfolio Planning: Competitive Benchmarking of Lung Cancer Pipeline by Investigator 10.1 Abbott 10.2 Abraxis BioScience 10.3 Active Biotech 10.4 Adherex 10.5 Advantagene 10.6 AEgera 10.7 Aeterna Zentaris 10.8 Agennix 10.9 Aida Pharmaceuticals 10.10 Alchemia 10.11 Alethia Biotherapeutics 10.12 Allos Therapeutics 10.13 Amgen 10.14 Antisense Pharma 10.15 Antisoma 10.16 Anza Therapeutics 10.17 ApopLogic Pharmaceuticals 10.18 Archer Biosciences 10.19 Ariad 10.20 ArQule 10.21 Array BioPharma 10.22 Ascenta Therapeutics 10.23 Astellas 10.24 AstraZeneca 10.25 Bayer 10.26 Biogen Idec 10.27 Biokine Therapeutics 10.28 BioNumerik 10.29 Boehringer Ingelheim 10.30 Bristol-Myers Squibb 10.31 BTG 10.32 CanBas 10.33 Celator Pharmaceuticals 10.34 Cell Genesys 10.35 Cell Therapeutics 10.36 Celtic Pharma 10.37 Center of Molecular Immunology 10.38 Cephalon 10.39 CG Therapeutics 10.40 Chemokine Therapeutics 10.41 Chong Kun Dang 10.42 Clavis Pharma 10.43 CLL Pharma 10.44 Critical Outcome Technologies 10.45 Cyclacel 10.46 CytImmune Sciences 10.47 Cytokinetics 10.48 Dabur Pharma 10.49 Daiichi Sankyo 10.50 Dainippon Sumitomo Pharma 10.51 Dara Biosciences 10.52 Dendreon 10.53 Dong-A 10.54 Eisai 10.55 Eli Lilly 10.56 Endocyte 10.57 EntreMed 10.58 EpiCept 10.59 Exelixis 10.60 Galapagos 10.61 Gemin X Pharmaceuticals 10.62 Genentech 10.63 Genmab 10.64 Genta 10.65 GenVec 10.66 Genzyme 10.67 Geron 10.68 GlaxoSmithKline 10.69 GlobeImmune 10.70 GlycoGenesys 10.71 Hana Biosciences 10.72 Hoffmann-La Roche 10.73 Human Genome Sciences 10.74 Idera Pharmaceuticals 10.75 ImClone Systems 10.76 ImmunoCellular Therapeutics 10.77 Immunocore 10.78 ImmunoGen 10.79 Immunomedics 10.80 Incyte Corporation 10.81 Infinity Pharmaceuticals 10.82 Innovive 10.83 Inovio 10.84 Introgen Therapeutics 10.85 Ipsen 10.86 Isis Pharmaceuticals 10.87 Jennerex Biotherapeutics 10.88 Johnson & Johnson 10.89 Kiadis 10.90 Kyowa Hakko Kirin 10.91 Lorus Therapeutics 10.92 MacroGenics 10.93 Medarex 10.94 MediGene 10.95 Medisyn Technologies 10.96 Menarini 10.97 Merck KGaA 10.98 MethylGene 10.99 Micromet 10.100 Mirna Therapeutics 10.101 MolMed 10.102 Mologen 10.103 Nektar Therapeutics 10.104 NeoPharm 10.105 Nerviano Medical Sciences 10.106 Novacea 10.107 Novartis 10.108 OncoGenex Pharmaceuticals 10.109 Oncothyreon 10.110 OSI Pharmaceuticals 10.111 OXiGENE 10.112 PanaGin 10.113 PBL Therapeutics 10.114 PDL BioPharma 10.115 Pfizer 10.116 Pharmacyclics 10.117 PharmaGap 10.118 PharmaMar 10.119 Pharmexa 10.120 Pierre Fabre 10.121 Pro-Pharmaceuticals 10.122 Progen 10.123 Protox Therapeutics 10.124 Receptor BioLogix 10.125 Regulon 10.126 RESprotect 10.127 Samyang 10.128 Sanofi-Aventis 10.129 Sareum 10.130 Schering-Plough 10.131 Seattle Genetics 10.132 ShimodaAtlantic Oncology 10.133 Shire 10.134 Sigma-Tau 10.135 Simcere Pharmaceuticals 10.136 SRI International 10.137 SuperGen 10.138 Supratek Pharma 10.139 Switch Pharma 10.140 Taiho 10.141 Takeda 10.142 Taxolog 10.143 Tekmira Pharmaceuticals 10.144 Telik 10.145 Thallion Pharmaceuticals 10.146 Therion Biologics 10.147 Titan Pharmaceuticals 10.148 Tracon Pharmaceuticals 10.149 Tragara Pharmaceuticals 10.150 Transgene 10.151 Trion Pharma 10.152 Twinstrand Therapeutics 10.153 UCB 10.154 Valeant 10.155 Vaxon Biotech 10.156 Vertex Pharmaceuticals 10.157 Vion Pharmaceuticals 10.158 ViRexx 10.159 Voyager Pharmaceutical 10.160 Wilex 10.161 Wyeth 10.162 Xerion 10.163 Xoma 10.164 Yakult Honsha 10.165 YM BioSciences 10.166 Zivena 10.167 Non-industrial Organizations 11 Disclaimer 12 Drug Index 13 Company Index 4.1 List of Figures Figure 1: Overall Breakdown of the Included Lung Cancer Therapeutic Pipeline by Sub-Indication and Stage of Development Figure 2: Visualization of Target-Target Interactions Among Lung Cancer Drug Targets Figure 3: The Drug-Protein Interactome of Lung Cancer Drugs –Clusters I Figure 4: The Drug-Protein Interactome of Lung Cancer Drugs – Clusters II Figure 5: Head-to-Head Targeting Interactome of Lung Cancer Drugs Figure 6: Distribution of Compound Types among Lung Cancer Drugs Figure 7: Primary Sub-cellular Localization of Drug Targets Figure 8: Breakdown of the Lung Cancer (general) Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development Figure 9: Compound Strategy Breakdown of the Lung Cancer (general) Pipeline Figure 10: Breakdown of the Non-Small Cell Lung Cancer Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development Figure 11: Compound Strategy Breakdown of the Non-Small Cell Lung Cancer Pipeline Figure 12: Breakdown of the Small Cell Lung Cancer Pipeline - Displaying Number of Drugs, Target Profiles and Investigators by Stage of Development Figure 13: Compound Strategy Breakdown of the Small Cell Lung Cancer Pipeline 4.2 List of Tables Table 1: Competitive Pressure Force Among Lung Cancer Drugs Table 2: Overview of Drug Target Profile Themes Table 3: Terminally Ceased Therapeutic Lung Cancer Targets Table 4: Drug Targets of Lung Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census Table 5: Identity of Lung Cancer Drug Targets with Available Biological Structures Table 6: Number of Target-Target Interactions among Lung Cancer Drug Targets Table 7: Drug-Protein Interactome Clusters Table 8: Lung Cancer Drug Targets with Available Protein Expression Profiles Table 9: Expression Levels of Identified Drug Targets in Lung Cancer Tissue Table 10: Pathway Summary Table 11: Drug Targets without any Identified Assigned Pathways Table 12: Pathway Profile According to BioCarta of Lung Cancer Drug Targets Table 13: Pathway Profile According to KEGG of Lung Cancer Drug Targets Table 14: Pathway Profile According to NetPath of Lung Cancer Drug Targets Table 15: Number of Drug Target Profiles by their Highest Developmental Stage and Uniqueness Table 16: Top Competitive Lung Cancer Target Profiles Table 17: Terminated Drug Target Strategies in Lung Cancer Table 18 New and Unique Lung Cancer Target Strategies in Pre-Registration to Marketed Table 19: New and Unique Lung Cancer Target Strategies in Phase III Clinical Development Table 20: New and Unique Lung Cancer Target Strategies in Phase II Clinical Development Table 21: The Competition Through Close Mechanistic Approximation Between Phase II Lung Cancer Drugs Table 22 New and Unique Lung Cancer Target Strategies in Phase I Clinical Development Table 23: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs Table 24: New and Unique Lung Cancer Target Strategies in Preclinical Development Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Lung Cancer Drugs Table 26: The Progression, Maturity and Competitive Comparison of Lung Cancer Drug Target Profiles in Development Table 27: Overview of Compound Strategy Competition in Lung Cancer Table 28:Overview of the Competitive Landscape of Small Molecular Drugs in Lung Cancer Table 29: Head-to-Head Target Competition Between Small Molecule Drugs for the Treatment of Lung Cancer Table 30: The Competition Through Close Mechanistic Approximation Between Small Molecule Drugs in Lung Cancer Table 31: The Progression, Maturity and Competitive Comparison of Target Profiles of Small Molecule Lung Cancer Drugs in Development Table 32: Overview of the Competitive Landscape of Peptide Based Drugs in Lung Cancer Table 33: The Progression, Maturity and Competitive Comparison of Target Profiles of Peptide Based Lung Cancer Drug in Development Table 34:Overview of the Competitive Landscape of Protein Based Drugs in Lung Cancer Table 35: The Competition Through Close Mechanistic Approximation Between Protein Based Drugs in Lung Cancer Table 36: The Progression, Maturity and Competitive Comparison of Protein Based Lung Cancer Drug Target Profiles in Development Table 37:Overview of the Competitive Landscape of Antibody Drugs in Lung Cancer Table 38: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Lung Cancer Table 39: The Progression, Maturity and Competitive Comparison of Target Profiles of Antibody Lung Cancer Drugs in Development Table 40:Overview of the Competitive Landscape of Nucleic Acid Therapy Drugs in Lung Cancer Table 41: The Progression, Maturity and Competitive Comparison of Target Profiles of Nucleic Acid Lung Cancer Drugs in Development Table 42: Vectors in Gene Therapy Table 43:Overview of the Competitive Landscape of Gene Therapy Drugs in Lung Cancer Table 44: The Competition Through Close Mechanistic Approximation Between Gene Therapy Drugs in Lung Cancer Table 45: The Progression, Maturity and Competitive Comparison of Target Profiles of Gene Therapy Lung Cancer Drugs in Development Table 46:Overview of the Competitive Landscape of Reformulated Drugs in Lung Cancer Table 47: The Competition Through Close Mechanistic Approximation Between Reformulated Drugs in Lung Cancer Table 48: The Progression, Maturity and Competitive Comparison of Target Profiles of Reformulated Lung Cancer Drugs in Development Table 49: The Competition Through Close Mechanistic Approximation Among Drugs in Lung Cancer Table 50: Compound Strategies based on Sub-Cellular Localization of Lung Cancer Drug Targets Table 51: Competitive Summary of Lung Cancer Drugs by Sub-Indication Table 52: Players in the Field of Lung Cancer (general) Drug Development and their Compared Pipeline Table 53: The Competition Through Close Mechanistic Approximation Between Lung Cancer (general) Drugs Table 54: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Lung Cancer (general) Drug Development Table 55: Players in the Field of Non-Small Cell Lung Cancer Drug Development and their Compared Pipeline Table 56: The Competition Through Close Mechanistic Approximation Between Non-Small Cell Lung Cancer Drugs Table 57: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Non-Small Cell Lung Cancer Drug Development Table 58: Players in the Field of Small Cell Lung Cancer Drug Development and their Compared Pipeline Table 59: The Competition Through Close Mechanistic Approximation Between Small Cell Lung Cancer Drugs Table 60: The Progression, Maturity and Competitive Comparison of Drug Target Profiles in Small Cell Lung Cancer Drug Development Table 61: Abbott's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 62: Abraxis BioScience's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 63: Active Biotech's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 64: Adherex's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 65: Advantagene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 66: AEgera's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 67: Aeterna Zentaris’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 68: Agennix's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 69: Aida Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 70: Alchemia's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 71: Alethia Biotherapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 72: Allos Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 73: Amgen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 74: Antisense Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 75: Antisoma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 76: Anza Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 77: ApopLogic Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 78: Archer Biosciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 79: Ariad's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 80: ArQule's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 81: Array BioPharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 82: Ascenta Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 83: Astellas’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 84: AstraZeneca's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 85: Bayer's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 86: Biogen Idec's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 87: Biokine Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 88: BioNumerik's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 89: Boehringer Ingelheim's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 90: Bristol-Myers Squibb's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 91: BTG's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 92: CanBas’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 93: Celator Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 94: Cell Genesys’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 95: Cell Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 96: Celtic Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 97: Center of Molecular Immunology's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 98: Cephalon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 99: CG Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 100: Chemokine Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 101: Chong Kun Dang's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 102: Clavis Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 103: CLL Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 104: Critical Outcome Technologies’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 105: Cyclacel's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 106: CytImmune Sciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 107: Cytokinetics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 108: Dabur Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 109: Daiichi Sankyo's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 110: Dainippon Sumitomo Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 111: Dara Biosciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 112: Dendreon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 113: Dong-A's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 114: Eisai's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 115: Eli Lilly's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 116: Endocyte's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 117: EntreMed's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 118: EpiCept's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 119: Exelixis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 120: Galapagos’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 121: Gemin X Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 122: Genentech's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 123: Genmab's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 124: Genta's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 125: GenVec's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 126: Genzyme's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 127: Geron's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 128: GlaxoSmithKline's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 129: GlobeImmune's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 130: GlycoGenesys’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 131: Hana Biosciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 132: Hoffmann-La Roche's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 133: Human Genome Sciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 134: Idera Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 135: ImClone Systems’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 136: ImmunoCellular Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 137: Immunocore's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 138: ImmunoGen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 139: Immunomedics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 140: Incyte Corporation's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 141: Infinity Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 142: Innovive's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 143: Inovio's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 144: Introgen Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 145: Ipsen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 146: Isis Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 147: Jennerex Biotherapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 148: Johnson & Johnson's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 149: Kiadis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 150: Kyowa Hakko Kirin's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 151: Lorus Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 152: MacroGenics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 153: Medarex's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 154: MediGene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 155: Medisyn Technologies’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 156: Menarini's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 157: Merck KGaA's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 158: MethylGene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 159: Micromet's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 160: Mirna Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 161: MolMed's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 162: Mologen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 163: Nektar Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 164: NeoPharm's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 165: Nerviano Medical Sciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 166: Novacea's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 167: Novartis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 168: OncoGenex Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 169: Oncothyreon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 170: OSI Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 171: OXiGENE's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 172: PanaGin's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 173: PBL Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 174: PDL BioPharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 175: Pfizer's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 176: Pharmacyclics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 177: PharmaGap's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 178: PharmaMar's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 179: Pharmexa's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 180: Pierre Fabre's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 181: Pro-Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 182: Progen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 183: Protox Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 184: Receptor BioLogix's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 185: Regulon's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 186: RESprotect's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 187: Samyang's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 188: Sanofi-Aventis’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 189: Sareum's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 190: Schering-Plough's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 191: Seattle Genetics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 192: ShimodaAtlantic Oncology's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 193: Shire's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 194: Sigma-Tau's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 195: Simcere Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 196: SRI International's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 197: SuperGen's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 198: Supratek Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 199: Switch Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 200: Taiho's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 201: Takeda's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 202: Taxolog's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 203: Tekmira Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 204: Telik's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 205: Thallion Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 206: Therion Biologics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 207: Titan Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 208: Tracon Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 209: Tragara Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 210: Transgene's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 211: Trion Pharma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 212: Twinstrand Therapeutics’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 213: UCB's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 214: Valeant's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 215: Vaxon Biotech's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 216: Vertex Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 217: Vion Pharmaceuticals’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 218: ViRexx's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 219: Voyager Pharmaceutical's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 220: Wilex's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 221: Wyeth's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 222: Xerion's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 223: Xoma's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 224: Yakult Honsha's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 225: YM BioSciences’ Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 226: Zivena's Included Lung Cancer Pipeline Composition and Competitive Fall-Out Table 227: Non-industrial source's Included Lung Cancer Pipeline Composition and Competitive Fall-Out

Companies Mentioned

- Abbott - Abraxis BioScience - Active Biotech - Adherex - Advantagene - AEgera - Aeterna Zentaris - Agennix - Aida Pharmaceuticals - Alchemia - Alethia Biotherapeutics - Allos Therapeutics - Amgen - Antisense Pharma - Antisoma - Anza Therapeutics - ApopLogic Pharmaceuticals - Archer Biosciences - Ariad - ArQule - Array BioPharma - Ascenta Therapeutics - Astellas - AstraZeneca - Bayer - Biogen Idec - Biokine Therapeutics - BioNumerik - Boehringer Ingelheim - Bristol-Myers Squibb - BTG - CanBas - Celator Pharmaceuticals - Cell Genesys - Cell Therapeutics - Celtic Pharma - Center of Molecular Immunology - Cephalon - CG Therapeutics - Chemokine Therapeutics - Chong Kun Dang - Clavis Pharma - CLL Pharma - Critical Outcome Technologies - Cyclacel - CytImmune Sciences - Cytokinetics - Dabur Pharma - Daiichi Sankyo - Dainippon Sumitomo Pharma - Dara Biosciences - Dendreon - Dong-A - Eisai - Eli Lilly - Endocyte - EntreMed - EpiCept - Exelixis - Galapagos - Gemin X Pharmaceuticals - Genentech - Genmab - Genta - GenVec - Genzyme - Geron - GlaxoSmithKline - GlobeImmune - GlycoGenesys - Hana Biosciences - Hoffmann-La Roche - Human Genome Sciences - Idera Pharmaceuticals - ImClone Systems - ImmunoCellular Therapeutics - Immunocore - ImmunoGen - Immunomedics - Incyte Corporation - Infinity Pharmaceuticals - Innovive - Inovio - Introgen Therapeutics - Ipsen - Isis Pharmaceuticals - Jennerex Biotherapeutics - Johnson & Johnson - Kiadis - Kyowa Hakko Kirin - Lorus Therapeutics - MacroGenics - Medarex - MediGene - Medisyn Technologies - Menarini - Merck KGaA - MethylGene - Micromet - Mirna Therapeutics - MolMed - Mologen - Nektar Therapeutics - NeoPharm - Nerviano Medical Sciences - Novacea - Novartis - OncoGenex Pharmaceuticals - Oncothyreon - OSI Pharmaceuticals - OXiGENE - PanaGin - PBL Therapeutics - PDL BioPharma - Pfizer - Pharmacyclics - PharmaGap - PharmaMar - Pharmexa - Pierre Fabre - Pro-Pharmaceuticals - Progen - Protox Therapeutics - Receptor BioLogix - Regulon - RESprotect - Samyang - Sanofi-Aventis - Sareum - Schering-Plough - Seattle Genetics - ShimodaAtlantic Oncology - Shire - Sigma-Tau - Simcere Pharmaceuticals - SRI International - SuperGen - Supratek Pharma - Switch Pharma - Taiho - Takeda - Taxolog - Tekmira Pharmaceuticals - Telik - Thallion Pharmaceuticals - Therion Biologics - Titan Pharmaceuticals - Tracon Pharmaceuticals - Tragara Pharmaceuticals - Transgene - Trion Pharma - Twinstrand Therapeutics - UCB - Valeant - Vaxon Biotech - Vertex Pharmaceuticals - Vion Pharmaceuticals - ViRexx - Voyager Pharmaceutical - Wilex - Wyeth - Xerion - Xoma - Yakult Honsha - YM BioSciences - Zivena